The US government has requested Germany’s support in its efforts to lower pharmaceutical prices. However, German Health Minister Nina Warken has indicated limited flexibility regarding this request. Germany currently maintains its own system for negotiating drug prices, which differs from the US approach. Warken’s stance suggests a reluctance to align with US demands, potentially due to concerns about access to affordable medication within Germany. The disagreement highlights ongoing international tensions surrounding pharmaceutical costs and healthcare policy. Further negotiations are anticipated, but a compromise remains uncertain given the firm position taken by the German health minister. This situation underscores the complexities of global drug pricing regulations.